Suggestions
Jens Eckstein
Biotech Founder and Investor
Jens Eckstein is a prominent figure in the life sciences and biopharma sectors, currently serving as a member of the Board of Directors at Vandria SA, a company focused on developing innovative therapeutics targeting age-related and chronic diseases through mitophagy inducers. His involvement with Vandria follows his recent appointment as an Investment Partner at the Hevolution Foundation, where he focuses on supporting healthy aging initiatives.
Professional Background
Eckstein has over 18 years of experience in biopharma venture capital and company creation, along with a decade of operational experience in drug discovery and development. Notably, he previously held the position of President at GlaxoSmithKline’s corporate venture fund, SR One, where he oversaw investments exceeding $500 million and was involved in numerous IPOs and M&A transactions.12
In addition to his role at Vandria, Eckstein is actively engaged in various advisory positions, including:
- Member of the Board of Advisors at Apollo Health Ventures
- President of Galilei Biosciences
- Advisor to multiple biotech companies such as Booster Therapeutics and Refoxy Pharma.1
Contributions to Vandria SA
Eckstein joined Vandria's board in August 2024 as part of a financing round that raised a total of CHF 30.7 million (approximately $33 million) for the company. His expertise is expected to significantly contribute to Vandria's mission to advance its lead compound, VNA-318, which is aimed at treating neurodegenerative diseases like Alzheimer's and Parkinson's.34
Education and Mentorship
He is also recognized as a Kauffman Fellow and serves on the EU-sponsored Gold Track Expert Council. Eckstein is passionate about mentoring entrepreneurs and start-up teams within the life sciences sector, further emphasizing his commitment to fostering innovation in healthcare.21
Language Proficiency
Eckstein is multilingual, with proficiency in English (native), German (native), and limited working proficiency in French.1
Overall, Jens Eckstein's extensive background in venture capital, combined with his leadership roles in various biotech ventures, positions him as a key player in advancing therapeutic solutions for aging-related health challenges.
